2.7(top 20%)
impact factor
2.7K(top 10%)
53.4K(top 5%)
81(top 10%)
3.0(top 20%)
extended IF
all documents
doc citations
116(top 10%)

Top Articles

1Current and future therapeutic approaches for osteosarcomaExpert Review of Anticancer Therapy2018539
2HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapiesExpert Review of Anticancer Therapy2011368
3Chemotherapy resistance in osteosarcoma: current challenges and future directionsExpert Review of Anticancer Therapy2006334
4Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitorExpert Review of Anticancer Therapy2007303
5Overview and recent advances in the treatment of neuroblastomaExpert Review of Anticancer Therapy2017286
6The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and careExpert Review of Anticancer Therapy2018268
7A new understanding in the epidemiology of melanomaExpert Review of Anticancer Therapy2010264
8Nonhistone protein acetylation as cancer therapy targetsExpert Review of Anticancer Therapy2010257
9Inflammation in the development of lung cancer: epidemiological evidenceExpert Review of Anticancer Therapy2008237
10Metastatic osteosarcoma: a challenging multidisciplinary treatmentExpert Review of Anticancer Therapy2016218
11Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumorsExpert Review of Anticancer Therapy2010215
12Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapyExpert Review of Anticancer Therapy2009206
13Head and neck cancer: past, present and futureExpert Review of Anticancer Therapy2006199
14Management of soft tissue sarcomas of the extremitiesExpert Review of Anticancer Therapy2004198
15Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastasesExpert Review of Anticancer Therapy2010177
16Nanotechnology for targeted cancer therapyExpert Review of Anticancer Therapy2007175
17Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancerExpert Review of Anticancer Therapy2018172
18The role of platelet activation in tumor metastasisExpert Review of Anticancer Therapy2008165
19A comprehensive review of protein kinase inhibitors for cancer therapyExpert Review of Anticancer Therapy2018164
20Oncolytic viruses: a novel form of immunotherapyExpert Review of Anticancer Therapy2008154
21Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cyclesExpert Review of Anticancer Therapy2016153
22Current systemic therapy for metastatic melanomaExpert Review of Anticancer Therapy2009151
23Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockadeExpert Review of Anticancer Therapy2012144
24Development of histone deacetylase inhibitors for cancer treatmentExpert Review of Anticancer Therapy2007141
25The role of Gliadel wafers in the treatment of high-grade gliomasExpert Review of Anticancer Therapy2013140
26Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesisExpert Review of Anticancer Therapy2004138
27Autophagy and endocrine resistance in breast cancerExpert Review of Anticancer Therapy2011137
28Stathmin 1: a novel therapeutic target for anticancer activityExpert Review of Anticancer Therapy2008130
29Recent advances in the prevention and treatment of skin cancer using photodynamic therapyExpert Review of Anticancer Therapy2010129
30MYC in breast tumor progressionExpert Review of Anticancer Therapy2008128
31Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic reviewExpert Review of Anticancer Therapy2017128
32Anti-GD2 immunotherapy for neuroblastomaExpert Review of Anticancer Therapy2017128
33MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st CenturyExpert Review of Anticancer Therapy2009126
34Screening of colorectal cancer: present and futureExpert Review of Anticancer Therapy2017123
35Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinomaExpert Review of Anticancer Therapy2004122
36Present and potential future issues in glioblastoma treatmentExpert Review of Anticancer Therapy2006120
37New treatment strategies for malignant gliomasExpert Review of Anticancer Therapy2006117
38Current epidemiological trends and surveillance issues in brain tumorsExpert Review of Anticancer Therapy2001116
39Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trialExpert Review of Anticancer Therapy2009116
40Bexarotene: a clinical reviewExpert Review of Anticancer Therapy2004111
41ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathwayExpert Review of Anticancer Therapy2012111
42The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic reviewExpert Review of Anticancer Therapy2017111
43Lapatinib in the treatment of breast cancerExpert Review of Anticancer Therapy2007110
44Review of image-guided radiation therapyExpert Review of Anticancer Therapy2007109
45Molecular mechanisms of temozolomide resistance in glioblastoma multiformeExpert Review of Anticancer Therapy2012109
46Optimizing treatment in recurrent epithelial ovarian cancerExpert Review of Anticancer Therapy2017107
47Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic routeExpert Review of Anticancer Therapy2019107
48The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapyExpert Review of Anticancer Therapy2016106
49Mathematical modeling of cancer progression and response to chemotherapyExpert Review of Anticancer Therapy2006105
50Muramyl tripeptide (mifamurtide) for the treatment of osteosarcomaExpert Review of Anticancer Therapy2009104